The multiple sclerosis (MS) drug interferon-beta is reported to not work for up to half of patients.
Researchers say they’ve figured out why a multiple sclerosis drug simply doesn’t work for up to half of patients.
The drug, called interferon-beta, can prevent flare-ups, but has unpleasant side effects and is expensive.
A new study in mice points to biological mechanisms that can lead to a form of MS that doesn’t respond to the drug. Researchers were able to identify new drug candidates that might help MS patients when interferon-beta treatment fails.
“The study shows a really clear molecular mechanism that may explain why some people do not respond to interferon-beta treatment,” says Mari Shinohara, an associate professor of immunology at Duke University and a senior author of the study in Nature Neuroscience. “We’ve found what makes a difference in the response.”
Read Full Article: Why this multiple sclerosis drug doesn’t work half the time – Futurity
|Read Full Article: Why this multiple sclerosis drug doesn’t work half the time – Futurity|